Video

Dr. Chughtai discusses new pilot study on Rezum treatment for BPH

“We found that the adverse event rates have dropped dramatically, to about a third of what it was reported in the pivotal trial, but at the same time still had the same net benefits in terms of efficacy when it comes to Q max, symptomatic improvement, as well as PVR," said Bilal Chughtai, MD.

In this video, Bilal Chughtai, MD, an associate professor of Urology at Weill Cornell Medical College, discusses the background and findings of his recent paper, "Pilot study of ‘less is more’ Rezum for treatment of BPH."

Related Videos
Ravi Munver, MD, answers a question during a Zoom video interview
Raevti Bole, MD, answers a question during a video interview
Illustration of Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Ravi Munver, MD, answers a question during a Zoom video interview
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Ravi Munver, MD, answers a question during a Zoom video interview
© 2024 MJH Life Sciences

All rights reserved.